FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2192016206> ?p ?o ?g. }

• W2192016206 endingPage "9" @default.
• W2192016206 startingPage "1" @default.
• W2192016206 abstract "The genetic and epigenetic alterations occurring during the course of multistage colorectal carcinogenesis have been extensively studied in the last few decades. One of the most notable findings is that the great majority of colorectal cancers (>80%) have mutations in the adenomatous polyposis coli (APC) tumor suppressor gene. Loss of functional APC protein results in activation of canonical Wnt/β-catanin signaling and initiates intestinal carcinogenesis. Mutational inactivation of APC is the first genetic event, but colorectal cancer cells retain their dependency on constitutive Wnt signal activation even after accumulation of other genetic events. Accordingly, pharmacological blocking of Wnt signaling has been considered an attractive therapeutic approach for colorectal cancer. Several therapeutics targeting various molecular components of the Wnt signaling pathway, including porcupine, frizzled receptors and co-receptor, tankyrases, and cAMP response element binding protein (CREB)-binding protein (CBP), have been developed, and some of those are currently being evaluated in early-phase clinical trials. Traf2- and Nck-interacting protein kinase (TNIK) has been identified as a regulatory component of the T-cell factor-4 and β-catenin transcriptional complex independently by two research groups. TNIK regulates Wnt signaling in the most downstream part of the pathway, and its inhibition is expected to block the signal even in colorectal cancer cells with APC gene mutation. Here we discuss some of the TNIK inhibitors under preclinical development." @default.
• W2192016206 created "2016-06-24" @default.
• W2192016206 creator A5011509062 @default.
• W2192016206 creator A5049388697 @default.
• W2192016206 creator A5075511892 @default.
• W2192016206 date "2015-12-01" @default.
• W2192016206 modified "2023-10-03" @default.
• W2192016206 title "Therapeutic targets in the Wnt signaling pathway: Feasibility of targeting TNIK in colorectal cancer" @default.
• W2192016206 cites W1018331845 @default.
• W2192016206 cites W1575128272 @default.
• W2192016206 cites W1963521777 @default.
• W2192016206 cites W1965700826 @default.
• W2192016206 cites W1966121721 @default.
• W2192016206 cites W1967137553 @default.
• W2192016206 cites W1969867759 @default.
• W2192016206 cites W1970195787 @default.
• W2192016206 cites W1971085650 @default.
• W2192016206 cites W1975423168 @default.
• W2192016206 cites W1975993620 @default.
• W2192016206 cites W1976359234 @default.
• W2192016206 cites W1982804269 @default.
• W2192016206 cites W1985158921 @default.
• W2192016206 cites W1986168751 @default.
• W2192016206 cites W1986724654 @default.
• W2192016206 cites W1988856936 @default.
• W2192016206 cites W1994029539 @default.
• W2192016206 cites W1999157957 @default.
• W2192016206 cites W2000991161 @default.
• W2192016206 cites W2001181621 @default.
• W2192016206 cites W2001459623 @default.
• W2192016206 cites W2002803432 @default.
• W2192016206 cites W2006307101 @default.
• W2192016206 cites W2006419043 @default.
• W2192016206 cites W2007145040 @default.
• W2192016206 cites W2008773040 @default.
• W2192016206 cites W2009117004 @default.
• W2192016206 cites W2009134460 @default.
• W2192016206 cites W2011517124 @default.
• W2192016206 cites W2011532943 @default.
• W2192016206 cites W2014886648 @default.
• W2192016206 cites W2018348035 @default.
• W2192016206 cites W2022083755 @default.
• W2192016206 cites W2023206317 @default.
• W2192016206 cites W2026041152 @default.
• W2192016206 cites W2032355637 @default.
• W2192016206 cites W2034030391 @default.
• W2192016206 cites W2034373020 @default.
• W2192016206 cites W2034820020 @default.
• W2192016206 cites W2045828622 @default.
• W2192016206 cites W2051055358 @default.
• W2192016206 cites W2055845643 @default.
• W2192016206 cites W2057257265 @default.
• W2192016206 cites W2059813946 @default.
• W2192016206 cites W2062006728 @default.
• W2192016206 cites W2069561533 @default.
• W2192016206 cites W2069750786 @default.
• W2192016206 cites W2071506358 @default.
• W2192016206 cites W2078591745 @default.
• W2192016206 cites W2078628823 @default.
• W2192016206 cites W2079554604 @default.
• W2192016206 cites W2086487946 @default.
• W2192016206 cites W2095579742 @default.
• W2192016206 cites W2096175781 @default.
• W2192016206 cites W2097959454 @default.
• W2192016206 cites W2101889783 @default.
• W2192016206 cites W2104452138 @default.
• W2192016206 cites W2105953048 @default.
• W2192016206 cites W2105986617 @default.
• W2192016206 cites W2107261560 @default.
• W2192016206 cites W2108981351 @default.
• W2192016206 cites W2112140640 @default.
• W2192016206 cites W2113995806 @default.
• W2192016206 cites W2115001053 @default.
• W2192016206 cites W2119032770 @default.
• W2192016206 cites W2126002765 @default.
• W2192016206 cites W2127396827 @default.
• W2192016206 cites W2132705689 @default.
• W2192016206 cites W2133267962 @default.
• W2192016206 cites W2147834058 @default.
• W2192016206 cites W2148074532 @default.
• W2192016206 cites W2154142433 @default.
• W2192016206 cites W2155978263 @default.
• W2192016206 cites W2158079348 @default.
• W2192016206 cites W2171080110 @default.
• W2192016206 cites W2239090104 @default.
• W2192016206 cites W2262414037 @default.
• W2192016206 cites W3083236858 @default.
• W2192016206 doi "https://doi.org/10.1016/j.pharmthera.2015.10.009" @default.
• W2192016206 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26542362" @default.
• W2192016206 hasPublicationYear "2015" @default.
• W2192016206 type Work @default.
• W2192016206 sameAs 2192016206 @default.
• W2192016206 citedByCount "62" @default.
• W2192016206 countsByYear W21920162062016 @default.
• W2192016206 countsByYear W21920162062017 @default.
• W2192016206 countsByYear W21920162062018 @default.
• W2192016206 countsByYear W21920162062019 @default.
• W2192016206 countsByYear W21920162062020 @default.

• next